Replication of JC virus (JCV) in oligodendrocytes, the myelin-producing cells of the central nervous system (CNS), results in the development of the human demyelinating disease progressive multifocal leukoencephalopathy (PML) (3). JCV is a polyomavirus which, like other members of this family, possesses a circular genome of double-stranded DNA within an icosahedral capsid (21). The prototype strain of JCV contains 5,130 bp which can be functionally divided into three regions: an early coding region, a late coding region, and a regulatory (noncoding) region (8). The regulatory region, which contains the promoters-enhancers for early and late gene transcription, as well as the origin of DNA replication, is located between the early and the late coding regions. The viral early gene encodes the viral regulatory proteins, large T antigen and small t antigen, whereas the late genes encode the structural capsid proteins, VP1, VP2, and VP3, as well as agnoprotein (20) . The viral lytic cycle begins with expression of the viral early protein, T antigen, which occurs before replication of the viral DNA. T antigen is a multifunctional protein which interacts with several host regulatory proteins and, by manipulating host gene expression and/or function, orchestrates subsequent steps of the viral life cycle including viral DNA replication (4) and activation of late gene transcription (17). The products of the late genes, the capsid proteins, accumulate in the nucleus and associate with the replicated viral DNA-forming virions which, in turn, lyse the host oligodendrocytes. Thus, T antigen acts as the central regulator of the viral lytic cycle. Further insights into the mechanism of JCV-induced oligodendrocyte dysfunction have been obtained from transgenic mice containing the JCV early genome under the control of the JCV early promoter. Some transgenic mouse lines display a characteristic shaking (23) similar to the phenotype in myelin-deficient jimpy and quaking mice (13, 22, 24) . Neuropathological analysis has shown hypomyelination in the CNS, high levels of JCV large T antigen in oligodendrocytes, immature oligodendrocytes with abnormal morphology, and hyperproliferating astrocytes with abnormal morphology (25). These observations demonstrate that dysmyelination in the CNS of transgenic animals, and perhaps demyelination in PML patients, is related at least partially to CNS T-antigen expression (7). Expression of the myelin-specific genes including that encoding myelin basic protein (MBP) in the brains of these transgenic mice is decreased at the mRNA level, suggesting that T antigen may impair transcriptional regulation of the MBP gene promoter (12). Similar to that of other cellular genes, transcription of the MBP gene is regulated by upstream promoter sequences which have the ability to interact with specific DNA-binding transcription factors (5, 18). Previous studies from our laboratory have identified a cellular protein, named MEF-1, from mouse brain nuclear extract that binds to a specific GC-rich region of the MBP gene promoter and stimulates its expression both in * Corresponding author. Mailing
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MEF-1/Pur␣ is a DNA-binding transcription factor first purified from mouse brains based on its ability to bind to the MBP gene promoter sequence and enhance its activity in oligodendrocytic cells (10, 12) . To assess the levels of MEF-1/ Pur␣ in the developing JCV transgenic mouse, JC91, which experiences CNS hypomyelination due to JCV T-antigen expression (11, 23) , and to compare Pur␣ levels with those from control littermates, protein extracts from mouse brains at various stages after birth were prepared and examined by immunoprecipitation-Western blot analysis. As illustrated in Fig. 1A  (top) , the level of MEF-1/Pur␣ was low in control mouse brain tissue at 10 days of age, increased at day 18, and remained fairly constant thereafter. The pattern of MEF-1/Pur␣ expression in the JC91 mouse brain during the course of brain development and its levels were similar to those from control animals (Fig. 1A, bottom) . The levels of MEF-1/Pur␣ in JC91, however, were marginally lower than those seen in control animals. These differences, however, may not account for the observed decrease in MBP gene expression. Since the activity of transcription factors may also be dictated by their association with other proteins, we sought to determine if MEF-1/ Pur␣, which is produced in transgenic mouse brain, is in a complex with JCV T antigen. Toward this end, protein extracts prepared from the brains of adult JC91 mice and the control age-matched littermates were prepared and used in coimmunoprecipitation-Western blot assays. Figure 1B (top) shows the presence of JCV T antigen in JC91 mouse brain, but not in the control animals, as determined by immunoprecipitation with antibody to T antigen followed by Western blotting with the same antibody. Next, the immunocomplexes precipitated upon incubation of the extracts from control and transgenic mouse brains by anti-T-antigen antibody were analyzed by Western blotting with anti-Pur␣ antibody. A band corresponding to MEF-1/Pur␣ was detected in immunocomplexes obtained from JC91 but not control animals (Fig. 1B , bottom, compare lane 1 to lane 2), suggesting that MEF-1/Pur␣ and T antigen are in a complex with each other in the protein extracts from the brains of transgenic animals. A band corresponding to MEF-1/Pur␣ was detected when brain extract of control animals was incubated with anti-Pur␣ antibody and analyzed by Western blotting (Fig. 1B , bottom, lane 3). These observations corroborate our earlier results, suggesting that MEF-1/Pur␣ and JCV T antigen interact with one another in both in vitro and in vivo systems (9) .
To compare levels of expression of the transgene and MEF-1/Pur␣ anatomically, we performed immunohistochemistry with monoclonal antibodies to T antigen and MEF-1/Pur␣. As illustrated in Fig. 2A , JCV T antigen was detected quite prominently in neurons, both in the dentate gyrus and in the pyramidal layer. Figure 2 also illustrates, at medium power, Tantigen-positive neurons in the hippocampus from JC91 mouse brain (B 1 ) and the parallel staining of the same cells with anti-MEF-1/Pur␣ antibody (B 2 ). As shown in this figure, MEF-1/Pur␣-positive staining overlaps with T antigen (compare panels B 1 and B 2 ). Also, it was noted that striations seen in white matter stained with MEF-1/Pur␣ (see arrowhead in Fig. 2B 2 ) are absent with T-antigen staining. Examination at high power of the white matter in close proximity to the hippocampus where oligodendrocytes are located for expression of T antigen and MEF-1/Pur␣ by immunostaining revealed production of T antigen in nuclei of oligodendrocytes. Figure   FIG. 1 . Level of MEF-1/Pur␣ in brains of JC91 and control age-matched mice during development. (A) Nuclear extracts from mouse brains at different stages of development (as indicated above the panels) were prepared according to the method described by Dignam et al. (6) . Approximately 100 g of extract from the controls (top) and JC91 (bottom) was incubated with 1 g of monoclonal 9C12 anti-Pur␣ antibody, and the immunocomplexes were analyzed by Western blotting with the anti-Pur␣ antibody as described previously (26) (Fig. 2C 1 , inset) . As expected, no T-antigen-positive cells were detected in the control samples. Immunostaining of the JC91 brain with anti-MEF-1/Pur␣ antibody showed nuclear and cytoplasmic staining of oligodendrocytes. As before, striation in the white matter along with oligodendrocytes was observed in JC91 brain staining (Fig. 2C 2 ) . Immunostaining of the control age-matched tissue revealed less nuclear staining of oligodendrocytes (Fig. 2C 2 , inset) .
To investigate the association of MEF-1/Pur␣ and T antigen at the subcellular level, we performed immunogold electron microscopy. Brains were perfusion fixed in 3.2% paraformaldehyde in phosphate-buffered saline and embedded in Unicryl. Ultrathin sections were cut, placed on Formvar-coated nickel grids, and treated sequentially for colocalization of T antigen and MEF-1/Pur␣. Tissues were initially stained with rabbit polyclonal anti-simian virus 40 T antigen, which recognizes JCV T antigen, followed by goat anti-rabbit antibody coupled to 10-nm gold beads. Sections were then incubated with antiPur␣ mouse monoclonal antibody followed by protein A coupled to 30-nm gold beads. The grids were examined with a JEOL JEM100CX electron microscope. Diameters of the gold beads indicate the magnification. For each pair of primary antibodies, the antibodies were tested alone and in both forward and reverse order to determine whether there was a difference in labeling patterns and efficiencies of labeling. Under the conditions described, no such differences were noted. Additional controls, employing either no first antibody or a glutathione S-transferase-Pur␣ blocking agent, were also performed to ensure specificity and the lack of cross-reactivity of the antibodies. The data were essentially negative (data not shown). Figure 3 illustrates, in a view with lower magnification, an oligodendrocyte (OL) with dense perinuclear chromatin positioned adjacent to a neuron (NU) (Fig. 3A) . Also in Fig. 3 , a low-magnification view of a nucleus of a large neuron with a single nucleolus is shown (Fig. 3B) . Evaluation of the printed photographs for colocalization of MEF-1/Pur␣ and T antigen revealed that many T-antigen (T) and MEF-1/Pur␣ (P) molecules in the nuclei of oligodendrocytes are adjacent to dense chromatin at the nuclear membrane ( Fig. 3C and D) . In many instances, the different molecules, MEF-1/Pur␣ (P) and T antigen (T), are detected within 10 nm of each other (PT). These data indicate that JCV T antigen is juxtaposed with MEF-1/ Pur␣ in the nuclei of oligodendrocytes of these transgenic mice.
Examination of hippocampal neurons by immunogold electron microscopy demonstrated T antigen in association with strands of diffuse chromatin just external to the nucleolus ( Fig.  3E and F) . In addition, several T-antigen molecules were detected in strand-like structures in juxtaposition with MEF-1/ Pur␣. It should be noted that, under similar conditions, immunogold staining of control age-matched mouse brain with anti-T-antigen antibody showed no specific signal to indicate that the T-antigen immunogold staining of the transgenic animal brain is specific. Furthermore, in corroboration with immunohistochemical data, particles corresponding to Pur␣ in control and transgenic samples were detected in the cytoplasm and nuclei (data not shown). These observations suggest that the JCV promoter can also be activated in neurons and that activation of the viral early promoter can result in expression of the viral early protein, T antigen, in these cells. Although there has been no report on neuronal expression of the JCV early genome in the demyelinating lesions from brains of PML patients, where active replication of the virus destroys oligodendrocytes, one may question whether, at the earlier stages of the disease, when demyelination has not been fully developed, the JCV early gene is expressed in the neurons. Currently, studies are in progress to assess the level of JCV early gene expression in the normal and less affected areas of brain from PML patients.
The association of MEF-1/Pur␣ with JCV T antigen might also serve to modulate the level of JCV transcription and replication during the course of the lytic cycle. To examine the level of MEF-1/Pur␣ interaction with JCV T antigen during viral infection, oligodendrocytic cells were prepared from CG-4 cells (19) and incubated with the Mad-1 strain of JCV ac- which express JCV T antigen (4). Interestingly, MEF-1/Pur␣ was associated with T antigen in these cells. Thus, it is likely that the observed inhibition of MEF-1/Pur␣ in JCV-infected oligodendrocytes is dependent on events involved in viral infection and not on T-antigen production. The observed suppression of MEF-1/Pur␣ expression during JCV lytic infection of oligodendrocytes, which is in contrast to the findings for transgenic animals expressing JCV T antigen (shown in Fig. 1A) , suggests that at least two distinct events may lead to JCV-induced hypomyelination of the CNS. Prior to active viral infection, expression of JCV T antigen and its association with MEF-1/Pur␣ may decrease the level of MBP gene expression and myelination. We have previously demonstrated that association of MEF-1/Pur␣ with T antigen also decreases the ability of T antigen to transactivate the JCV late promoter, an event which is important for a productive JCV lytic cycle. Thus, one can envision a model in which, at the earlier stage of the disease when the level of T antigen is low, interaction of T antigen with MEF-1/Pur␣ may prevent MEF-1/Pur␣ from exerting its regulatory activity in oligodendrocytes. This interaction, which also blocks T antigen from stimulating the late stage of the viral infection cycle, prolongs the early stage and permits continuous production of T antigen in the affected cells. As the level of T antigen is increased, the unoccupied protein eventually guides the virus through the lytic cycle, causing cytolytic destruction of oligodendrocytes. Consistent with a number of animal viruses, the lytic infection of JCV seems to be associated with inhibited expression of some cellular genes including MEF-1/Pur␣. While JC91 transgenic mice are an important tool for studying the interaction of viral and host factors in the CNS, they do not provide a perfect animal model for the human demyelinating disease, PML. A complete understanding of PML progression in the human CNS must await studies with systems which allow virus expression in a more natural setting.
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